However, a clinical trial (EVOLVE-1) of the MTOR inhibitor, everolimus, showed that it did not improve overall survival in advanced HCC patients unresponsive or intolerant to sorafenib [30]. The gene discussed is MTOR; the disease is hepatocellular carcinoma.